Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway

• Main Authors: Xiaobo Zhang (Author), Yicheng Liu (Author), Lu Lu (Author), Shaoliang Huang (Author), Youxiang Ding (Author), Yi Zhang (Author), Qinglong Guo (Author), Zhiyu Li (Author), Li Zhao (Author)
• Format: Book
• Published: Frontiers Media S.A., 2017-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Imatinib (IM), as first inhibitor of the oncogenic tyrosine kinase BCR-ABL, has been widely used to treat chronic myeloid leukemia (CML) for decades in clinic. However, resistance to IM usually occurs in CML patients. The bone marrow (BM), as the predominant microenvironment of CML, secretes an abun...